Aceto Corporation (ACET): Price and Financial Metrics


Aceto Corporation (ACET): $14.58

-0.02 (-0.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ACET to Watchlist
Sign Up

Industry: Chemicals


Ranked

of

in industry

ACET POWR Grades


  • ACET scores best on the Sentiment dimension, with a Sentiment rank ahead of 81.19% of US stocks.
  • ACET's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • ACET ranks lowest in Momentum; there it ranks in the 4th percentile.

ACET Stock Summary

  • Adicet Bio Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 8.58% of US listed stocks.
  • With a price/sales ratio of 77.71, Adicet Bio Inc has a higher such ratio than 97.14% of stocks in our set.
  • Revenue growth over the past 12 months for Adicet Bio Inc comes in at -45.65%, a number that bests only 3.54% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Adicet Bio Inc, a group of peers worth examining would be ONCT, SLDB, FDMT, CRBP, and CCCC.
  • Visit ACET's SEC page to see the company's official filings. To visit the company's web site, go to www.restorbio.com.

ACET Valuation Summary

  • In comparison to the median Healthcare stock, ACET's price/earnings ratio is 113.15% lower, now standing at -4.8.
  • Over the past 44 months, ACET's price/sales ratio has gone NA NA.
  • Over the past 44 months, ACET's EV/EBIT ratio has gone up 12.2.

Below are key valuation metrics over time for ACET.

Stock Date P/S P/B P/E EV/EBIT
ACET 2021-08-31 28.7 1.2 -4.8 -1.3
ACET 2021-08-30 27.5 1.1 -4.6 -1.1
ACET 2021-08-27 27.7 1.1 -4.6 -1.1
ACET 2021-08-26 26.4 1.1 -4.4 -0.9
ACET 2021-08-25 25.2 1.0 -4.2 -0.7
ACET 2021-08-24 25.0 1.0 -4.1 -0.7

ACET's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACET has a Quality Grade of D, ranking ahead of 8.53% of graded US stocks.
  • ACET's asset turnover comes in at 0.043 -- ranking 330th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ACET's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.043 1 -1.841
2021-03-31 0.027 1 -2.369
2020-12-31 0.157 1 -2.317
2020-09-30 0.031 1 -3.142
2020-06-30 0.000 NA -1.790
2020-03-31 0.000 NA -1.243

ACET Price Target

For more insight on analysts targets of ACET, see our ACET price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $28.29 Average Broker Recommendation 1.21 (Strong Buy)

ACET Stock Price Chart Interactive Chart >

Price chart for ACET

ACET Price/Volume Stats

Current price $14.58 52-week high $21.17
Prev. close $14.60 52-week low $6.25
Day low $14.56 Volume 96,159
Day high $14.98 Avg. volume 482,224
50-day MA $12.66 Dividend yield N/A
200-day MA $12.63 Market Cap 583.26M

Aceto Corporation (ACET) Company Bio


Aceto Corporation sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The company was founded in 1947 and is based in Port Washington, New York.


ACET Latest News Stream


Event/Time News Detail
Loading, please wait...

ACET Latest Social Stream


Loading social stream, please wait...

View Full ACET Social Stream

Latest ACET News From Around the Web

Below are the latest news stories about Adicet Bio Inc that investors may wish to consider to help them evaluate ACET as an investment opportunity.

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

Adicet Bio (ACET) was founded in 2014 and is based in Boston, Massachusetts. The company’s platform is based on gamma delta T cells, which have been major investor attention recently. The first generation of CAR T therapies was based on alpha beta T cells and had issues with durability and...

Bhavneesh Sharma on Seeking Alpha | February 9, 2022

Analysts Are Bullish on These Healthcare Stocks: Adicet Bio (ACET), Marinus (MRNS)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adicet Bio (ACET – Research Report) and Marinus (MRNS – Research Report) with bullish sentiments. Adicet Bio (ACET) H.C. Wainwright analyst Edward White reiterated a Buy rating on Adicet Bio today and set a price target of $35.00. The company's shares closed last Thursday at $12.13. According to TipRanks.

Christine Brown on TipRanks | February 4, 2022

JMP Securities Remains a Buy on Adicet Bio (ACET)

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Adicet Bio (ACET – Research Report), with a price target of $30.00. The company's shares closed last Thursday at $12.30. According to TipRanks.com, Benjamin is ranked 0 out of 5 stars with an average return of -12.0% and a 31.8% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $32.00 average price target, a 158.1% upside from current levels.

Brian Anderson on TipRanks | February 3, 2022

Adicet Bio to Participate in Guggenheim 2022 Oncology Conference

MENLO PARK, Calif. & BOSTON, February 02, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2022 Oncology Conference taking place virtually on February 9-11, 2022.

Yahoo | February 2, 2022

Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

MENLO PARK, Calif. and BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock, at a pub

Yahoo | December 10, 2021

Read More 'ACET' Stories Here

ACET Price Returns

1-mo 29.14%
3-mo -29.94%
6-mo -16.64%
1-year 50.31%
3-year -79.74%
5-year N/A
YTD -16.64%
2021 24.48%
2020 34.71%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5021 seconds.